Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ACADEMIA
ACADEMIA
- Dapagliflozin Significantly Reduces Plasma Glucose in PIII Study in Japan, Findings Reported at ADA
June 25, 2013
- SCJ Statement Calls for Close Consultation with Experts in Planning Japanese Version of NIH
June 25, 2013
- Makers Should Venture into Drug Development Using iPS, CiRA Adviser Asonuma Says
June 25, 2013
- More Treatment Options for FD Patients with Acofide Launch: Prof. Kinoshita of Shimane University
June 11, 2013
- Clinical Pharmacology Network to Go Into Operation with 8 Institutions
June 6, 2013
- Japan College of Rheumatology Issues Guidelines on Xeljanz Use
June 6, 2013
- Cetuximab Add-on Therapy Fails to Improve PFS in Operable Colorectal Liver Metastasis Patients: ASCO
June 4, 2013
- Japan College of Rheumatology to Collaborate with Pfizer on PMS, Warns that Non-RA Specialists More Inclined to Prescribe Xeljanz
May 31, 2013
- Researcher Wearing Two Hats Should Disclose Affiliation with Greater Interests in Trials: Japan Hypertension Society
May 30, 2013
- JAMS Recognizes Violation of COI Reporting Rules over Diovan Papers
May 28, 2013
- Nat’l University Hospitals Sharing Information of Drug Purchase Prices through Central Database
May 7, 2013
- JAMS Greatly Concerned Over Diovan Paper Retractions: President Takaku
April 25, 2013
- Stivarga May Become Third/Forth-Line Colon Cancer Therapy in Japan: Prof. Sugihara
April 25, 2013
- RA Treatment Guidelines to Reflect Patients’ Values and Economic Considerations as Well as Evidence
April 24, 2013
- Osaka University Hospital to Initiate PET Microdose Study This Fall: Prof. Tomono
April 23, 2013
- New COPD Guidelines Recommend LAMA, LABA on Equal Footing
April 23, 2013
- Japan College of Rheumatology Airs Concerns over Safety of Xeljanz
April 11, 2013
- Kyoto Heart Study Chief Investigator Resigns after Diovan Paper Retractions
March 1, 2013
- Diovan Paper Contained “Careless Errors,” but “No Impact on Findings”: Chief Investigator Comments on Retraction
February 7, 2013
- JSGM Calls for 80% Generic Share, 30% Reduction in NHI Prices of Long-Listed Drugs by End of FY2017
December 6, 2012
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…